The METSSAR trial investigates a new dosing schedule for #selinexor in soft tissue sarcoma patients. The split-dose approach shows promising safety and tolerability, with no grade ≥ 3 adverse events reported. https://t.co/mwBWjHvZzN

A multicenter study from Japan shows that combining baseline NLR and ΔNLR can help identify NSCLC patients who may benefit most from chemoimmunotherapy, providing valuable prognostic insights. https://t.co/iKuwvcIAJg #openaccess #immunotherapy #NSCLC

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of #Lenvatinib Clinical Trials: A Systematic Review https://t.co/RoZGmu495Z

Efficacy and Safety of Docetaxel plus #Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients https://t.co/Equ8mf5cwL #NSCLC

Impact of AML1/ETO Fusion on the Efficacy of #Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia https://t.co/NMaBerkAMa #AML #openaccess

#Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia—A #Podcast https://t.co/0hLPcKfbnX #ALL #openaccess

A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G https://t.co/YYjqePonhC #mCRC #openccess

EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation https://t.co/PonEBgefgX

Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial #OvarianCancer: A Nationwide Propensity Score Matched Cohort Study https://t.co/eDOm4eA1nR

Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data https://t.co/77EI6Aredm #openaccess

Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk #Neuroblastoma: A Systematic Literature Review https://t.co/s7L1fv6qfk #openaccess

DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic #Melanoma https://t.co/3O6ZiugTKs #immunotherapy #openaccess

Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab https://t.co/o2RV1rODIj #immunotherapy #BTC

Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of #Immunotherapy https://t.co/7iFxz3XP6A #mRCC #openaccess

#Lenvatinib Versus #Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies https://t.co/w7LBPbaTmh #HCC #immunotherapy

#Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08) https://t.co/DwxTvjnJZ2 #HNSCC

Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China https://t.co/V9bWoHDaoP

Safety and Efficacy of #Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma https://t.co/ZQoOsoNhOU #HCC

Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer https://t.co/OhndJ0PfbX #mCRC

Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea https://t.co/OXkBhTbp6t